Bicara Therapeutics Inc. (BCAX)
NASDAQ: BCAX · Real-Time Price · USD
18.20
-0.56 (-2.99%)
Dec 5, 2025, 4:00 PM EST - Market closed
Bicara Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Bicara Therapeutics stock have an average target of 26.2, with a low estimate of 11 and a high estimate of 40. The average target predicts an increase of 43.96% from the current stock price of 18.20.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Bicara Therapeutics stock from 5 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 1 | 1 |
| Buy | 3 | 4 | 4 | 4 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 8 | 8 | 8 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Hold Maintains $8 → $11 | Hold | Maintains | $8 → $11 | -39.56% | Nov 11, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $41 → $40 | Strong Buy | Maintains | $41 → $40 | +119.78% | Aug 22, 2025 |
| Piper Sandler | Piper Sandler | Buy Initiates $36 | Buy | Initiates | $36 | +97.80% | Aug 19, 2025 |
| Wells Fargo | Wells Fargo | Sell → Hold Upgrades $8 | Sell → Hold | Upgrades | $8 | -56.04% | May 23, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $44 → $41 | Strong Buy | Maintains | $44 → $41 | +125.27% | May 16, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.56
from -4.05
EPS Next Year
-3.10
from -2.56
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -2.46 | -2.43 | ||||
| Avg | -2.56 | -3.10 | ||||
| Low | -2.55 | -3.38 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.